NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced the appointment of Executive Chairman Amir Heshmatpour as the company's new President, while maintaining his role as Executive Chairman. This strategic move aims to accelerate the company's clinical initiatives, particularly focusing on central nervous system (CNS) cancers and disorders.
Heshmatpour brings over 25 years of executive experience, notably founding AFH Holdings & Advisory where he led IPO transactions worth over $1.5 billion and M&A deals exceeding $5 billion. His previous success includes founding Metrophone Telecommunications, which under his leadership completed 17 acquisitions and achieved annual revenues over $100 million.
In his expanded role, Heshmatpour will oversee daily operations while enabling CEO Dr. Thomas Chen to focus on advancing clinical trials, particularly patient enrollment for lead drug candidates NEO212 (TMZ bio-conjugate) and NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) ha annunciato la nomina del Presidente Esecutivo Amir Heshmatpour come nuovo Presidente dell'azienda, mantenendo il suo ruolo di Presidente Esecutivo. Questa mossa strategica mira ad accelerare le iniziative cliniche dell'azienda, con particolare attenzione ai tumori e ai disturbi del sistema nervoso centrale (CNS).
Heshmatpour porta con sé oltre 25 anni di esperienza dirigenziale, avendo fondato AFH Holdings & Advisory, dove ha guidato transazioni IPO per un valore superiore a 1,5 miliardi di dollari e operazioni di M&A superiori a 5 miliardi di dollari. Il suo successo precedente include la fondazione di Metrophone Telecommunications, che sotto la sua guida ha completato 17 acquisizioni e raggiunto ricavi annuali superiori a 100 milioni di dollari.
Nel suo ruolo ampliato, Heshmatpour supervisionerà le operazioni quotidiane, consentendo al CEO Dr. Thomas Chen di concentrarsi sull'avanzamento delle sperimentazioni cliniche, in particolare sull'arruolamento dei pazienti per i principali candidati farmaceutici NEO212 (bio-coniugato di TMZ) e NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) ha anunciado el nombramiento del Presidente Ejecutivo Amir Heshmatpour como nuevo Presidente de la empresa, manteniendo su rol como Presidente Ejecutivo. Este movimiento estratégico tiene como objetivo acelerar las iniciativas clínicas de la empresa, centrándose particularmente en los cánceres y trastornos del sistema nervioso central (CNS).
Heshmatpour aporta más de 25 años de experiencia ejecutiva, habiendo fundado AFH Holdings & Advisory, donde lideró transacciones de IPO por un valor de más de 1.5 mil millones de dólares y acuerdos de M&A que superan los 5 mil millones de dólares. Su éxito previo incluye la fundación de Metrophone Telecommunications, que bajo su liderazgo completó 17 adquisiciones y alcanzó ingresos anuales de más de 100 millones de dólares.
En su rol ampliado, Heshmatpour supervisará las operaciones diarias, permitiendo al CEO Dr. Thomas Chen concentrarse en avanzar en los ensayos clínicos, particularmente en la inscripción de pacientes para los principales candidatos a fármacos NEO212 (bio-conjugado de TMZ) y NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI)는 Amir Heshmatpour를 새로운 사장으로 임명하고 그의 역할인 집행 의장을 유지한다고 발표했습니다. 이 전략적 결정은 회사의 임상 이니셔티브를 가속화하는 것을 목표로 하며, 특히 중추신경계(CNS) 암 및 장애에 중점을 두고 있습니다.
Heshmatpour는 25년 이상의 경영 경험을 가지고 있으며, AFH Holdings & Advisory를 설립하여 15억 달러 이상의 IPO 거래와 50억 달러 이상의 M&A 거래를 이끌었습니다. 그의 이전 성공에는 Metrophone Telecommunications의 설립이 포함되며, 그는 이끌면서 17건의 인수를 완료하고 연간 수익이 1억 달러를 초과했습니다.
확대된 역할에서 Heshmatpour는 일상적인 운영을 감독하며, CEO Dr. Thomas Chen이 임상 시험을 진행하는 데 집중할 수 있도록 하여, 특히 주요 약물 후보인 NEO212 (TMZ 바이오-결합체) 및 NEO100의 환자 등록을 촉진할 것입니다.
NeOnc Technologies Holdings (NASDAQ: NTHI) a annoncé la nomination de son Président Exécutif Amir Heshmatpour en tant que nouveau Président de l'entreprise, tout en conservant son rôle de Président Exécutif. Ce mouvement stratégique vise à accélérer les initiatives cliniques de l'entreprise, en se concentrant particulièrement sur les cancers et les troubles du système nerveux central (CNS).
Heshmatpour apporte plus de 25 ans d'expérience exécutive, ayant notamment fondé AFH Holdings & Advisory, où il a dirigé des transactions d'introduction en bourse d'une valeur de plus de 1,5 milliard de dollars et des opérations de fusion-acquisition dépassant les 5 milliards de dollars. Son succès précédent inclut la fondation de Metrophone Telecommunications, qui, sous sa direction, a réalisé 17 acquisitions et atteint des revenus annuels de plus de 100 millions de dollars.
Dans son rôle élargi, Heshmatpour supervisera les opérations quotidiennes tout en permettant au PDG Dr. Thomas Chen de se concentrer sur l'avancement des essais cliniques, en particulier l'inscription des patients pour les principaux candidats médicaments NEO212 (bio-conjugué de TMZ) et NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) hat die Ernennung von Executive Chairman Amir Heshmatpour zum neuen Präsidenten des Unternehmens bekannt gegeben, während er seine Rolle als Executive Chairman beibehält. Dieser strategische Schritt zielt darauf ab, die klinischen Initiativen des Unternehmens zu beschleunigen, insbesondere mit Fokus auf Krebs und Störungen des zentralen Nervensystems (CNS).
Heshmatpour bringt über 25 Jahre Führungserfahrung mit, insbesondere als Gründer von AFH Holdings & Advisory, wo er IPO-Transaktionen im Wert von über 1,5 Milliarden Dollar und M&A-Deals über 5 Milliarden Dollar leitete. Zu seinen bisherigen Erfolgen gehört die Gründung von Metrophone Telecommunications, das unter seiner Leitung 17 Übernahmen abschloss und jährliche Einnahmen von über 100 Millionen Dollar erzielte.
In seiner erweiterten Rolle wird Heshmatpour die täglichen Abläufe überwachen und es CEO Dr. Thomas Chen ermöglichen, sich auf die Förderung klinischer Studien zu konzentrieren, insbesondere auf die Patientenrekrutierung für die Hauptmedikamentenkandidaten NEO212 (TMZ-Bio-Konjugat) und NEO100.
- Experienced leadership addition with proven track record of $1.5B in IPO transactions
- Strategic restructuring allows CEO to focus exclusively on clinical trial advancement
- Leadership has demonstrated success in M&A with over $5B in transaction value
- Previous business success growing company to $100M annual revenue through acquisitions
- Clinical trials still in early stages requiring significant patient enrollment
- Multiple leadership roles concentrated in one person could create governance concerns
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company’s strategic and clinical initiatives.
“Amir’s appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs,” said Dr. Thomas Chen, CEO of NeOnc. “His extensive experience in building and scaling companies, coupled with his deep understanding of capital markets and business development, will be instrumental as we move forward.”
Heshmatpour brings over 25 years of senior executive and board-level experience in business development, operations, finance, and M&A. He is the founder, chairman, and managing director of AFH Holdings & Advisory, where he has led IPO transactions totaling over
Previously, Heshmatpour served as Chairman and CEO of Metrophone Telecommunications, which he founded in 1994. Under his leadership, Metrophone completed 17 acquisitions and grew annual revenues to over
“I’m honored to step into the role of President at such a pivotal time in NeOnc’s evolution. By formalizing my day-to-day oversight of Company operations, we’re enabling Dr. Chen to focus fully on driving our clinical trials forward, with a specific emphasis on patient enrollment for our lead drug candidates — NEO212, our TMZ bio-conjugate, and NEO100,” said Heshmatpour. “With our promising drug candidates advancing through clinical development, I’m confident in our ability to deliver significant value to patients, providers, and shareholders alike.”
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonctech.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com/lberman@pondel.com
FAQ
What is the significance of Amir Heshmatpour's appointment as President of NTHI?
What are NTHI's main drug candidates currently in development?
What is Amir Heshmatpour's track record in business leadership?
How will NTHI's leadership structure change with this appointment?
